Trial Profile
A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; Rituximab (Primary) ; Utomilumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 02 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2018 Planned End Date changed from 30 Sep 2024 to 30 Oct 2024.